Remedy for Chronic Inflammation and Antibody to be Used Therein

ABSTRACT

The invention provides a remedy for chronic inflammation and an anti-TNIIIA2 antibody to be used therein. The remedy includes an antibody recognizing TNIIIA2, that is a peptide derived from a partial sequence A2 of a human tenascin-C fibronectin III-like repetitive sequence and having the amino acid sequence RSTDLPGLKAATHYTITIRGVC (SEQ ID NO: 1).

TECHNICAL FIELD

The present invention relates to a remedy for chronic inflammation and anovel antibody to be used therein.

BACKGROUND ART

The expression of tenascin-C is rarely observed in healthy cells, exceptfor the immune system. Expression of tenascin-C is induced underpathological conditions such as inflammation and tumor growth.

As a method for detecting tenascin-C, some anti-tenascin-C antibodieshave been known (for example, see JP-A Nos. 2004-217546 and2002-234900). An arthritis diagnosis method using tenascin-C as a markerhas been also known (for example, see JP-A-2004-138489).

A polypeptide which forms tenascin-C includes an epidermal growthfactor-like domain, a fibronectin (FN) III-like domain and afibrinogen-like domain. Among them, it has been known that the FNIII-like domain includes a continuation between 8 basic types ofrepetitive sequences (1 to 8) and 9 types of repetitive sequences to bespliced (A1, A2, A3, A4, B, AD2, AD1, C and D), which are insertedbetween the fifth and the sixth sequences of the 8 basic types thereof.These repetitive sequence sites to be spliced are those easily cut bymatrix metalloproteinases (MMP), and a peptide produced by a cut intenascin-C by MMP are thought as having various functions.

On the other hand, it has been known that, in chronic inflammation,immune cells including monocytes such as macrophages and lymphocytesinfiltrate from the blood vessels into the vascular endothelium andpenetrate through the vascular basement membrane to gather at aninflammatory site. Such an immune cell infiltration at the inflammatorysite is regulated by the interaction between immune cells, vascularendothelial cells and extracellular matrixes via adhesion molecules,integrins, on the immune cell membrane. It has been known that theintegrins exist in two conformations, the active form and the inactiveform and only the active form of integrins can adhere to extracellularmatrixes.

A peptide derived from the A2 domain of the FNIII-like domain oftenascin-C (hereinafter may be referred to as “TNIIIA2”) has been knownas a peptide causing the activation of the integrins (for example, seeJ. Biol. Chem., Vol. 282, pp. 34929-34937 (2007)).

However, no details have been given as to the roles of tenascin-C andthe peptide derived therefrom in inflammatory sites, and in particular,there has been obtained no clear finding regarding their relationshipwith chronic inflammation. Further, there are cases that the effects ofconventionally-known anti-tenascin-C antibodies against inflammation areinconsistent depending on the site.

SUMMARY

An object of the present invention is to provide a novel remedyeffective against chronic inflammation.

A first aspect of the present invention provides an anti-TNIIIA2antibody recognizing a peptide derived from a partial sequence A2 of ahuman tenascin-C fibronectin III-like repetitive sequence. The antibodypreferably recognizes a peptide having the amino acid sequence of SEQ IDNO: 1.

A second aspect of the present invention provides an immune cellvascular infiltration inhibitor including the antibody.

A third aspect of the present invention provides a cell death inducerfor inflammatory cells, including the antibody.

A fourth aspect of the present invention provides a chronic inflammationremedy including the antibody.

The present invention can provide the novel remedy against chronicinflammation.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a view showing the inhibition effects of anti-human TNIIIA2antibodies against cell adhesion induced by a peptide TNIIIA2, accordingto Example 1 of the invention.

DESCRIPTION OF EMBODIMENTS

An antibody according to the invention is an anti-TNIIIA2 antibodyrecognizing a peptide derived from a partial sequence A2 of a humantenascin-C fibronectin III-like repetitive sequence.

The antibody recognizes the peptide (TNIIIA2) derived from the partialsequence A2 present in the human tenascin-C fibronectin III-likerepetitive sequence. The antibody selectively binds to the TNIIIA2,thereby inhibiting immune cell infiltration that can be induced by theTNIIIA2.

The present inventor found that the peptide TNIIIA2 derived from humantenascin-C is associated with the infiltration of immune cells and acell death-inducing mechanism for inflammatory cells in inflammationsites. The invention is based on this finding.

In the present description, the term “step” encompasses not onlyindependent steps but a case in which even if a step cannot be clearlydistinguished from any other step, as long as an effect expected fromthe step is achieved.

Additionally, in the present description, the numerical range indicatedby using “to” refers to a range including respective values presentedbefore and after “to” as a minimum and a maximum, respectively.

Hereinafter, the invention will be described.

The anti-TNIIIA2 antibody of the invention is not specifically limitedas long as the antibody can recognize the peptide (TNIIIA2) derived fromthe partial sequence A2 of the human tenascin-C FNIII-like domain. Theanti-TNIIIA2 antibody may be a monoclonal antibody or a polyclonalantibody.

The TNIIIA2 is a peptide composed of 22 amino acids:RSTDLPGLKAATHYTITIRGVC (SEQ ID NO: 1) (See J. Biol. Chem., Vol. 282, pp.34929-34937 (2007)). The anti-TNIIIA2 antibody of the invention is theantibody that recognizes the TNIIIA2, in which at least a part of theamino acid sequence of the TNIIIA2 shown in SEQ ID NO: 1 is an epitope.The epitope recognized by the anti-TNIIIA2 can be any as long as it is apartial peptide including an amino acid sequence: YTITIRGV (SEQ ID NO:2).

The peptide to be used to produce the antibody that recognizes theTNIIIA2, namely the peptide (a target peptide) recognized by theanti-TNIIIA2 antibody can be any peptide as long as the peptide includesthe sequence of SEQ ID NO: 2, and in embodiments it may be a peptidehaving the entire length (SEQ ID NO: 1). From the viewpoint of improvingantigenicity and stability, a linker function or one or more compoundshaving a linker function (for example, an amino acid) may be added tothe peptide having the amino acid sequence of SEQ ID NO: 2. Examples ofsuch an additional amino acid include amino acids capable of adding anamino acid to be bound to a carrier protein to the peptide having theamino acid sequence of SEQ ID NO: 2, such as cysteine, acidic aminoacids or basic amino acids. From the viewpoint of antibody productionefficiency, it may be more preferable that the target peptide has anamino acid sequence: CATHTITIRGV (SEQ ID NO: 3).

The antibody recognizing the TNIIIA2 can be prepared using the targetpeptide by a usually-conducted method.

For example, when the antibody is a polyclonal antibody, it may beobtained in the following manner. Any of the amino acid sequences of SEQID NOs: 1 to 3 or a mixture thereof is used as the target peptide. Thetarget peptide is used to immunize a small animal such as a rabbit toobtain serum. The antibody is then prepared by purification thereof fromthe obtained serum by using a known antibody-purifying means, such asammonium sulfate precipitation, protein A, protein G columns, DEAEion-exchange chromatography, or affinity columns prepared by couplingthe specific peptide.

Alternatively, when the antibody is a monoclonal antibody, it may beobtained in the following manner. Any small animal such as a mouse isimmunized with the target peptide. A spleen is taken out of the mouseand crushed to isolate cells. The spleen cells are fused with mousemyeloma cells by using a reagent such as polyethylene glycol to formfused cells (hybridomas). Clones which produce antibodies binding to thetarget peptide are selected from hybridomas. Next, the selectedhybridomas are transplanted in the peritoneal cavity of a mouse tocollect ascitic fluid from the mouse. The obtained monoclonal antibodyis purified by, for example, ammonium sulfate precipitation, protein A,protein G columns, DEAE ion-exchange chromatography or affinity columnsprepared by coupling the specific peptide, so as to prepare theantibody.

The target peptide may be used in immunization in a form of a fusionprotein in which the by target peptide is fused with a known carrierprotein in view of improving antigenicity. Any known molecule used forthis purpose can be used as such a carrier protein without any specificrestriction, and examples of the carrier protein include KLH, GST andBSA.

The immune cells the infiltration of which is inhibited by theanti-TNIIIA2 antibody are not specifically restricted as long as theyare immune cells the infiltration of which is observed in inflammatorysites. Examples of such immune cells include neutrophils, eosinophils,basophils, monocytes, lymphocytes (including plasma cells) andcombinations of two or more kinds thereof.

Not being restricted by any specific theory, it is expected that theanti-TNIIIA2 antibody can inhibit the adhesion of immune cells to anextracellular matrix (for example, fibronectin or the like) by hamperingthe activation of integrins expressed on the immune cell surface inducedby tenascin-C or the like. Therefore, the use of the anti-TNIIIA2antibody may inhibit occurrence of immune cell infiltration across thevascular endothelium.

In addition, at an inflammatory site in chronic inflammation, activatedresident immune cells or immune cell infiltrate (these cells aresometimes generically called “inflammatory cells”) are known to existfor a longer period of time than usual. The anti-TNIIIA2 antibody caninduce the cell death of such inflammatory cells, thereby inhibitingtheir long-term existence.

A chronic inflammation remedy according to the invention includes atleast the anti-TNIIIA2 antibody.

Inclusion of the anti-TNIIIA2 antibody may allow for the inhibition ofimmune cell infiltration into an inflammatory site and may also allowfor the induction of cell death of the inflammatory cells to inhibit thelonger existence of the inflammatory cells, whereby chronic inflammationcan be treated.

Subjects of treatment with the chronic inflammation remedy may bepreferably mammals, and more preferably humans.

The chronic inflammation remedy according to the invention may beadministered orally or parenterally, and systemically or locally.Examples of the selectable administration method include intravenousinjection such as drip infusion, intramuscular injection,intraperitoneal injection, subcutaneous injection, suppository, enema,oral enteric tablet and the like. The administration method can beselected as appropriate, depending on patients' age and condition ofdisease. In addition, the amount of administration can also be selectedas appropriate, depending on patients' age, condition of disease and thelike.

The chronic inflammation remedy may further include a carrier and/or anadditive that are pharmaceutically acceptable in accordance with theadministration route. Examples of such a carrier and an additive includewater, pharmaceutically acceptable organic solvents, collagen, polyvinylalcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, carboxymethylcellulose sodium, sodium polyacrylate, sodium alginate, water-solubledextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethylcellulose, xanthan gum, gum arabic, casein, gelatin, agar, diglycerin,propylene glycol, polyethylene glycol, Vaseline, paraffin, stearylalcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol,lactose and surfactants acceptable as pharmaceutical additives. Theadditives to be used may be selected as appropriate from the aboveexamples in accordance with the dosage form, but not limited thereto.

An immune cell infiltration inhibitor according to the inventionincludes at least the anti-TNIIIA2 antibody.

Inclusion of the anti-TNIIIA2 antibody may allow for the inhibition ofinfiltration of immune cells into the vascular endothelium and effectssuch as chronic inflammation inhibition or the like can be exhibited.

The immune cell infiltration inhibitor may further include any othercomponent if needed. The carriers and additives pharmaceuticallyacceptable in the chronic inflammation remedy may be similarly used assuch other components.

A cell death inducer for inflammatory cells according to the inventionincludes at least the anti-TNIIIA2 antibody. Inclusion of theanti-TNIIIA2 antibody may allow for the induction of cell death ofinflammatory cells at an inflammatory site, thereby inhibiting theirlong-term existence and to exhibits effects such as alleviation ofsymptoms due to chronic inflammation.

The cell death inducer for inflammatory cells may further include anyother component if needed. The carriers and additives pharmaceuticallyacceptable in the chronic inflammation remedy may be similarly used assuch other components.

The invention further includes a method for treating or inhibitingchronic inflammation, the method including administration of the remedyincluding the anti-TNIIIA2 antibody to patients who have or may developchronic inflammation. Herein, any improvement in symptoms is included inthe scope of the “treating chronic inflammation”, and thus alleviationof symptoms and inhibition of advances in severity are also includedtherein. Symptoms of chronic inflammation or symptoms occurring due toinflammation can be inhibited, reduced or alleviated thereby.

The amount of administration in patients may be different depending onthe dosage form of a remedy to be applied, patients' sex, age, symptomsand the like or combinations thereof. In general, administration can bedone by intravenous injection, intramuscular injection, intraperitonealinjection, subcutaneous injection, suppository, enema and oral enterictablet, and preferably by intravenous injection.

The method of administration to patients are different depending on thedosage form of a remedy to be applied, patients' sex, age, symptoms andthe like or combinations thereof, and, in general, examples of theadministration method can include intravenous injection, intramuscularinjection, intraperitoneal injection, subcutaneous injection,suppository, enema and oral enteric tablet. From these administrationmethods, an appropriate method may be selected depending on thecondition of the patient. The effective dose of the antibody intreatment may vary depending on the level of symptom and the conditionof the patient. In embodiments, it may be in a range of fromapproximately 0.1 mg/kg weight to approximately 50 mg/kg weight, but notlimited thereto. In addition, the frequency of administration may beset, for example, in a range of twice per daily to once per week, butnot limited thereto.

EXAMPLES

Hereinafter, the invention will be described by way of Examples, but theinvention is not limited to these Examples. Unless specifically statedotherwise, “%” is based on mass.

Example 1 <Production of Anti-Human TNIIIA2 Antibody>

A peptide having the amino acid sequence of SEQ ID NO: 3 was synthesizedby a usual method. The synthesized peptide as hapten was fused with KLH,and the obtained fusion peptide was used as an antigenic peptide.Immunization was conducted in accordance with a usual method usingrabbits. The mixture including a target antibody obtained was purifiedby a usual method.

In the manner as above, three kinds (No. 1 to No. 3) of polyclonalantibodies (anti-human TNIIIA2 antibodies) against the human TNIIIA2were obtained.

<Evaluation of Antibody Activity>

Antibody activity of the anti-human TNIIIA2 polyclonal antibodiesobtained above were evaluated as follows by using, as indicators, theirinhibition effects against cell adhesion induced by the human TNIIIA2.The results are shown in Table 1.

Using RPMI 1640 (20% FBS added) as a cell culture medium, KOP 2.16 cells(a mouse bone marrow-derived vascular endothelial cell line) were seededin each well of a 96-hole plate at a density of 5×10⁴ cells/200 μL/wellto be cultured at 37° C. and 5% CO₂ for 4 hours. After 100 μL of theculture supernatant was removed and 100 μL of 20% TCA solution wasadded, the cells were allowed to stand at 4° C. overnight or at roomtemperature for 1 hour to be solid-phased. The plate was washed 5 timeswith PBS, once with RPMI 1640 (20% FBS added) and once with PBS in thisorder to produce a 96-hole plate with each well coated with KOP 2.16cells.

Into each well of the 96-hole plate coated with KOP 2.16 cells obtainedabove was added RPMI 1640 (20% FBS added) containing 12.5 μg/mL of thehuman TNIIIA2. The anti-human TNIIIA2 antibodies (No. 1 to No. 3)obtained above were added such that their concentrations were 1.5 μg/mL,3 μg/mL and 6 μg/mL, respectively, and then, K562 cells (a leukemia cellline) were seeded in each well at the density of 1.5×10⁴ cells/well tobe cultured at 37° C. and 5% CO₂ for 1 hour.

Following the addition of formalin, the cells were allowed to stand atroom temperature for 1 hour to be immobilized. Then, the plate waswashed three times with PBS and stained with Lily Mayer's Hematoxylin.The stained cells were observed with an optical microscope to countadherent cells in a predetermined visual field.

FIG. 1 indicates that the normal rabbit IgG does not inhibit celladhesion induced by the human TNIIIA2, whereas the anti-human TNIIIA2antibodies dose-dependently inhibit cell adhesion. In addition, all ofthe anti-human TNIIIA2 antibodies of No. 1 to No. 3 are shown to exhibitsimilar degrees of antibody activity. Further, the anti-human TNIIIA2antibodies did not exhibit inhibition effect against cell adhesioninduced by magnesium ion.

The above results show that the anti-human TNIIIA2 antibody of theinvention may specifically bind to the human TNIIIA2 to inhibit itsfunction.

[Example 2]

<Evaluation 1 of Infiltration Inhibiting Properties>

The inhibition of infiltration of Jurkat cells (a T cell-based cellline) into the vascular endothelium by the anti-human TNIIIA2 antibodywas evaluated as follows.

Into each well of a 96-hole plate, human tenascin-C at a concentrationof 5 μg/mL was added, and the cells were incubated at 37° C. for 1 hour.The plate was blocked by adding BSA at a concentration of 2.5 mg/mL andincubating at 37° C. for 1 hour. The plate was washed three times withPBS to obtain an assay well plate with each well coated withhuman-tenascin C.

Next, into each well of the assay well plate, KOP 2.16 (the mouse bonemarrow-derived vascular endothelial cell line) suspended in a DMEM (+)culture medium was seeded so as to be the condition of 5.0×10⁴cells/well and cultured at 37° C. and 5% CO₂ for 3 hours. Thereby, asingle layer composed of the KOP 2.16 cells was formed on the wellscoated with human tenascin-C.

A normal rabbit IgG or the anti-human tenascin-C antibody was added to asuspension of Jurkat cells such that its concentration was 20 μg/mL. Theresulting cells were gently seeded on the single layer composed of theKOP 2.16 cells at a density of .1.0×10⁴ cells/well and cultured at 37°C. and 5% CO₂ for 3 hours.

After adding formalin and allowing to stand at room temperature for more1 hour to be immobilized, the cells were washed three times with PBS (−)and stained with Lily Mayer's Hematoxylin. Under an optical microscope(at 200-fold magnification), the numbers of infiltration inpredetermined four fields were counted concerning each three wells andan arithmetic average value thereof was determined as an infiltrationcount.

The infiltration count in a case without adding the human tenascin-Cwere similarly calculated and was used as a background to subtract fromthe infiltration count of the human tenascin-C-added sample, wherebyobtained infiltration counts is shown in Table 1. Further, the ratio ofa difference between the infiltration count of a sample using the normalrabbit IgG and that of the sample using the anti-human TNIIIA2 antibodyto the infiltration count of the sample using the normal rabbit IgG wascalculated as an infiltration inhibition rate (%).

In addition, the inhibition of THP-1 infiltration into the vascularendothelium by the anti-human TNIIIA2 antibody was evaluated in the samemanner as above, except that THP-1 (a monocytes-like cell line) was usedinstead of the Jurkat cells. The results are shown in Table 1.

TABLE 1 Jurkat THP-1 Normal rabbit IgG 27 41 Anti-human TNIIIA2 antibody7 1 Infiltration inhibition rate (%) 74% 98%

Table 1 indicates that the anti-human TNIIIA2 antibody can effectivelyinhibit the infiltration of 1-lymphocyte cells or monocytes-like cellsinto the vascular endothelial layer induced by human tenascin-C.

Example 3 <Evaluation 2 of Infiltration Inhibiting Properties>

The infiltration inhibition effect of the anti-human TnIIIA2 antibodyobtained in Example 1 was compared with those of another antibody 4F10TTand a normal rabbit IgG, against human tenascin-C as follows.

The 4F10TT is a rabbit IgG antibody that recognizes a peptide sequenceof the epithelium growth factor-like domain of human tenascin-C. The4F10TT used here was obtained from Immuno-Biological Laboratories Co.,Ltd (Tsunoda T. et al., Am J Pathol 162: 1857-1867, 2003; Sato A. etal., J Am Coll Cardiol 47: 2319-2325, 2006).

The count of Jurkat cells which infiltrated into the single layer of theKOP 2.16 cells was measured in the same manner as in Example 2 exceptthat the above antibodies were respectively used.

The infiltration count in a case without adding any antibody wassimilarly counted. The ratio of the infiltration count of each case ofthe addition of the normal mouse IgG (normal IgG), the addition of the4F10TT, and the addition of the anti-human TNIIIA2 antibody to theinfiltration count obtained without adding any antibody were calculated.The results are shown in Table 2 (“Coated TNC”).

Additionally, the cell infiltration inhibition effect of each antibodywas evaluated in the same manner as above, except that, instead of theassay plate with each well coated with human tenascin-C, an uncoated96-hole plate was prepared and human tenascin-C was added at aconcentration of 2 μg/mL to bring the total volume per well to 100 μL.The results are shown in Table 2 (“Soluble TNC”).

TABLE 2 Antibody Coated TNC Soluble TNC — 1 1 Normal IgG 1.05 1.054F10TT 1.04 1.07 Anti-TNIIIA2 0.74 0.84

The results of Table 2 indicate that the cell infiltration inhibitioneffects of the antibodies recognizing the human tenascin-C-derivedpeptide differ from each other, and the anti-TNIIIA2 antibody shows aremarkable cell infiltration inhibition effect as compared to the4F10TT.

Example 3 <Evaluation of Long-Term Existence Inhibiting Properties>

The effect of the anti-human TNIIIA2 antibody on changes in viablemacrophage cell counts over time in the presence of human tenascin-C wasevaluated as follows.

THP-1 cells were cultured in a complete medium, to which PMA was addedat a concentration of 10 ng/mL, at 37° C. and 5% CO₂ for 24 hours to beinduced to differentiate into macrophages (hereinafter, thedifferentiated THP-1 is referred to as “PMA-THP-1”).

Into each well of a 96-hole plate, fibronectin (FN) was added at aconcentration of 5 μg/mL, and the plate was incubated at 37° C. for 1hour. The plate was blocked by adding BSA at a concentration of 2.5mg/mL and incubating at 37° C. for 1 hour, and washed three times withPBS to obtain a plate with FN-coated each well.

Into the FN-coated wells, an RPMI 1640 (serum-free) culture medium, towhich human tenascin-C was added such that its final concentration was 2μg/mL, was added, and a normal rabbit IgG, the 4F10TT antibody or theanti-human TNIIIA2 antibody was further added to bring its finalconcentration to 50 μg/mL. Herein, PMA-THP-1 cells were seeded to bringthe density to 2×10⁴ cells/well to 2.5×10⁴ cells/well and cultured at37° C. and 5% CO₂ for 24 hours.

Using a cell counting kit (manufactured by DOUJIN Co.) based on the WSTmethod, cell counts were measured to calculate the ratio (viable cellcount ratio) of post-culture viable cell counts (day 2) to viable cellcounts upon seeding (day 0). The results are shown in Table 3.

TABLE 3 Antibody Cell count ratio Day 0 1 Day 2 — 1.52 1 Normal IgG 1.480.97 4F10TT 1.57 1.03 Anti-TNIIIA2 0.93 0.61

Table 3 shows the increase of the macrophages in the presence of humantenascin-C. On the contrary, it is shown that, when the anti-humanTNIIIA2 antibody is added, increase in the macrophages was inhibited(the ratio of the cell count thereof to that of no antibody-additionsample is 0.61), and the viable cell count decreased (the ratio of thecell count thereof to that measured upon seeding is 0.93). In otherwords, it is found that the anti-human TNIIIA2 antibody can inhibitlong-term existence of the macrophages in the presence of humantenascin-C.

It was observed that the decrease in the viable cell count by theanti-human TNIIIA2 antibody was due to cell death.

It is understood from the above that the anti-human TNIIA2 antibody ofthe invention may inhibit immune cell infiltration into the vascularendothelium and may induce the cell death of inflammatory cells in thepresence of human tenascin-C.

The disclosure of Japanese Patent Application No. 2009-025707 filed onFeb. 6, 2009 is incorporated herein by reference in its entirety.

All documents, patent applications and technical standards described inthe present description are incorporated herein by reference to the sameextent as if each individual document, patent application and technicalstandard were specifically and individually indicated to be incorporatedby reference.

1. An antibody recognizing a peptide derived from a partial sequence A2of a human Tenascin-C fibronectin III-like repetitive sequence.
 2. Theantibody of claim 1 that recognizes a peptide having the amino acidsequence of SEQ ID NO:
 2. 3. An immune cell infiltration inhibitorcomprising the antibody of claim
 1. 4. A cell death inducer forinflammatory cells, the cell death inducer comprising the antibody ofclaim
 1. 5. A chronic inflammation remedy comprising the antibody ofclaim
 1. 6. The antibody of claim 1 that recognizes a peptide having theamino acid sequence of SEQ ID NO:
 1. 7. The antibody of claim 1 thatrecognizes an antigen, the antigen being a fusion protein containing ahapten, the hapten having the amino acid sequence of SEQ ID NO:
 3. 8. Animmune cell infiltration inhibitor comprising the antibody of claim 2.9. A cell death inducer for inflammatory cells, the cell death inducercomprising the antibody of claim
 2. 10. A chronic inflammation remedycomprising the antibody of claim
 2. 11. An immune cell infiltrationinhibitor comprising the antibody of claim
 6. 12. A cell death inducerfor inflammatory cells, the cell death inducer comprising the antibodyof claim
 6. 13. A chronic inflammation remedy comprising the antibody ofclaim
 6. 14. An immune cell infiltration inhibitor comprising theantibody of claim
 7. 15. A cell death inducer for inflammatory cells,the cell death inducer comprising the antibody of claim
 7. 16. A chronicinflammation remedy comprising the antibody of claim 7.